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PURPOSE. The purpose of this study was to evaluate meibomian gland dropout and lipid layer
thickness (LLT) in patients with and without Sjo¨gren’s syndrome dry eye (SS).
METHODS. We recruited 11 participants with SS (males/females [M/F], 1:10; mean age ¼ 56.0
6 9.1 years) and 10 control subjects without dry eye (M/F, 3:7; mean age ¼ 58.5 6 4.7 years).
All participants completed the Ocular Surface Disease Index (OSDI) questionnaire. The LLT
was assessed using the Tearscope Plus based on the appearance of the lipid layer. Noninvasive
tear break-up time (NITBUT) also was measured. The lower and upper lids were everted, and
the meibomian glands were imaged using the infrared camera of the Keratograph 4. A
meibomian gland dropout score due to gland loss was obtained. Statistical analysis was
conducted using the Mann-Whitney U test and correlations were determined using Spearman
rank correlations.
RESULTS. Of the SS participants, 100% reported ocular and oral dryness symptoms in the AECC
questionnaire. The SS group recorded a higher OSDI score (median ¼ 48.00, interquartile
range [IQR] 23.0–56.2 vs. 2.1, IQR 0.0–2.6; P < 0.001), reduced LLT (median [IQR] ¼ 15.0
[15.0–15.0] vs. 60.0 [45.0–100.0] nm; P ¼ 0.001), and lower NITBUT (median [IQR] ¼ 3.7
[2.5–4.2] vs. 9.5 [6.4–17.6] sec; P < 0.001) compared to the controls. Digital meibomian
gland dropout score (% dropout) was significantly higher for the SS group (16.0% [IQR 12.1–
40.0%] vs. 6.7% [IQR 1.5–12.7%]; P ¼ 0.01). Subjective meibomian gland dropout score (0–6
score) was significantly higher for the SS group (median [IQR] ¼ 1.5 [1.0–4.0] vs. 1.0 [0.0–
1.25]; P ¼ 0.03).
CONCLUSIONS. Patients with SS showed higher meibomian gland dropout scores and reduced
LLT and NITBUT, which likely contribute to the severe dry eye symptoms reported by SS
subjects.
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Sjo¨gren’s syndrome (SS) is a disease characterized byinfiltration of lymphocytes into exocrine glands, including
sebaceous, sweat, salivary, and lacrimal glands.1–4 Following
infiltration, gland atrophy and dysfunction occurs.1,5 The
disease manifests with moderate-to-severe dry eye and dry
mouth, and may occur in combination with other systemic
manifestations.1,3,5,6 Sjo¨gren’s syndrome is not curable and
typically is not diagnosed until irreversible organ damage has
occurred.1,5 The disease affects 3.1 million North Americans,
including approximately 430,000 Canadians, with 90% of those
affected being women.1,7 The prevalence of primary SS in
China has been reported to be 0.77%8 and in the United
Kingdom to be 0.1%.9 Controversy exists regarding age of onset
of the disease, with one report suggesting two peaks in life
during which there is an increased risk of onset, at 20 to 30
years of age and after the mid-50s.10 However, others report
that the average age of onset is 45 years.1,5
While patients with SS exhibit dry eye symptoms and signs,
it is not possible to diagnose the condition using ocular
symptoms and signs alone. The American-European Consensus
Group developed a list of six criteria to help diagnose SS.6 For
positive diagnosis, at least four of six of the criteria must be
met, with at least one of the four criteria met being positive for
the autoantibodies Ro and/or La, or a positive salivary gland
biopsy score ( ‡1 focus score of 4 mm of tissue). More recently,
the American College of Rheumatology has proposed an expert
consensus approach to the diagnosis of SS, with revised
considerations for positive diagnosis to at least two of three
criteria. The three criteria include (1) positive serum anti-SSA/
Ro and/or anti-SSB/La, or (positive rheumatoid factor and ANA
titer ‡1:320); (2) labial salivary gland biopsy exhibiting focal
lymphocytic sialadenitis with a focus score ‡1 focus/4 mm; and
(3) keratoconjunctivitis sicca with ocular staining score ‡3
(assuming that individual is not currently using daily eye drops
for glaucoma and has not had corneal surgery or cosmetic
eyelid surgery in the last 5 years).11 The revised classification
criteria were not available at the time of this study and, thus,
were not used for classification of SS.
Sjo¨gren’s syndrome has been classified as aqueous-deficient
dry eye by the International Dry Eye Workshop, with much
attention being paid to the lack of aqueous tear production.12
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However, meibomian gland dysfunction also has been diag-
nosed in patients with SS.13
Meibomian glands are sebaceous glands located in the tarsal
plates of the upper and lower eyelids. There are approximately
30 to 40 glands in the upper lid and 20 to 30 glands in the
lower lid.14 These glands secrete the lipid layer of the tear film
onto the surface of the eye, which helps prevent rapid
evaporation of the tear film and subsequent ocular discom-
fort.14 Meibomian gland dysfunction (MGD) has been classified
by the International Workshop on Meibomian Gland Dysfunc-
tion as a chronic, diffuse abnormality of the meibomian glands,
commonly characterized by terminal duct gland obstruction
and/or qualitative/quantitative changes in the glandular secre-
tion. This may result in alteration of the tear film, symptoms of
eye irritation, clinically apparent inflammation, and ocular
surface disease.15 Meibomian gland dysfunction increases with
age, contact lens wear, and androgen deficiency.16–19 This
would suggest that the severe dry eye signs and symptoms seen
in SS may be due to a lack of tear production and also poor tear
quality, due to a reduced lipid layer. However, the degree of
meibomian gland loss in SS patients requires further investiga-
tion.
Historically, the presence of MGD has been evaluated based
on characteristics of secretion quality and quantity from the
glands, as well as gland orifice plugging. Currently, user-
friendly techniques are available to image the actual ‘‘dropout’’
of the meibomian glands from the upper and lower lids via the
use of an infrared camera.20,21 Dropout of meibomian glands is
considered areas of the lids that appear to have glands missing
or have truncated glands, from areas that should histologically
have meibomian glands. These areas of loss appear as dark
areas on the images of the lids, compared to the white-colored
area of the glands. To date, only one study has used the use of
meibography to evaluate MGD in SS patients13 and to our
knowledge, no studies have compared meibography to the
measured lipid layer thickness (LLT) in such patients. Thus, the
purpose of this study was to evaluate and compare meibomian
gland dropout and LLT in patients with and without SS dry eye.
METHODS
Approval of this project was granted through the Office of
Research Ethics at the University of Waterloo, and all
procedures adhered to the Declaration of Helsinki. Participants
were recruited at the Centre for Contact Lens Research and
Ocular Health Clinic at the School of Optometry and Vision
Science, University of Waterloo. Written informed consent was
obtained from each participant after explanation of the
purpose of the study and study procedures to be undertaken.
A total of 21 participants completed the study. Current and
past contact lens wearers and participants with lid abnormal-
ities (e.g., stye, chalazion, trichiasis, or coloboma) that would
interfere with lid eversion were excluded from the study.
The study was a one-visit study consisting of two parts: Part
1 consisted of a screening visit, including Ocular Surface
Disease Index (OSDI) questionnaire, biomicroscopic assess-
ment, staining assessment, followed by a break of 30 minutes;
and part 2 included collection of primary outcome variables,
LLT, lid parallel conjunctival folds (LIPCOF), noninvasive tear
breakup time (NITBUT), meibomian gland expression, and
meibography.
All assessments were carried out by the same examiner.
Participant Categorization
Participants were categorized into two groups: an SS group and
a control group. Participants who were diagnosed previously
with SS, who had symptoms of dry eye and discomfort for at
least 3 months, and a staining score of >4 of 9 in at least one
eye were placed into the SS group. Participants with no
previous diagnosis of SS who reported an OSDI score of
1222,23 and who showed a staining score of 1 of 9 for both
eyes were included in the control group.
Those in the SS group also were asked questions regarding
their dry eye and dry mouth symptoms. These questions are
included in the American-European Consensus Group Crite-
ria.6
Staining Assessment
A grading scale adopted from the scales created by van
Bijsterveld,24 the Oxford grading scale,25 and members of the
Sjo¨gren’s International Collaborative Clinical Alliance (SIC-
CA)26 was used to grade corneal and conjunctival cell staining.
Sodium fluorescein dye (strips obtained from Flu Glo; Akorn,
Inc., Lakeforest, IL, USA) was used to assess corneal staining.
Staining of the conjunctiva was assessed after the instillation of
lissamine green dye (strips obtained from Green Glo; Sigma
Pharmaceuticals, Monticello, IA, USA). Three zones were
graded for staining: the temporal conjunctiva, cornea, and
nasal conjunctiva. Staining in each zone was graded accord-
ingly: 0, no staining; 1, few separate spots; 2, many separate
spots; and 3, confluent spots. Conjunctival and corneal
staining scores were combined, as proposed by the Ameri-
can-European Consensus Group Criteria for diagnosis of SS;
thus, total scores for each eye ranged between 0 (no staining)
and 9 (confluent staining in all zones).
LLT Evaluation
The tear film LLT was measured for each participant using the
Keeler Tearscope Plus (Keeler Instruments, Inc., Broomall, PA,
USA), as described previously.27–29 The lipid layer for each
participant was graded by appearance using the system
described by Guillon and Guillon.30 Lipid layer classification
was given a quantitative value,30,31 for subsequent statistical
analysis.
Lid Parallel Conjunctival Folds (LIPCOF)
The presence of LIPCOF was examined on the inferior
temporal region of the conjunctiva along the lower lid margin
just outside of the limbal region.32 The LIPCOF for each
participant was graded using Hoh’s grading scale (grade 0, no
permanently present fold; grade 1, single, small fold, less than
tear prism height; grade 2, multiple folds, up to the tear prism
height; grade 3, multiple folds, higher than tear prism
height).32–34
Noninvasive Tear Breakup Time (NITBUT)
The NITBUT was measured using the Atlas Corneal Topogra-
pher (Carl Zeiss Meditec Ag, Oberkochen, Germany). The
participant was instructed to blink three consecutive times and
then asked to hold his/her eyes open for as long as possible.
The time elapsed between the last blink and first sign of
distortion occurring of the ring pattern was recorded as the
NITBUT. This was repeated three times for each eye and the
average reported.
Meibomian Gland Expressibility and Secretion
Quality
Obstruction of the meibomian gland orifices and quality of
gland expression were evaluated using the gland evaluator
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developed by Korb et al.35 The device was designed to apply a
constant force of 1.25g/mm2. The pressure was applied for
approximately 12 to 15 seconds before the instrument was
removed. The number of glands within central eight glands of
the lower lid that did not express was recorded. Meibum that
expressed from the glands was evaluated using a 0 to 3 scale:
grade 0, normal, clear oil expressed (cooking oil appearance);
grade 1, opaque, diffusely turbid, normal viscosity; grade 2,
opaque, increased viscosity; and grade 3, inspissated (i.e.,
toothpaste-like) or unable to express any material.36
Meibography
The meibomian glands were imaged using the infrared camera
system of the Keratograph 4 (Oculus, Wetzlar, Germany), as
described previously.20 Meibomian gland dropout was first
evaluated subjectively using a 0 to 3 grading scale developed by
Arita et al.17,36,37 (grade 0, no gland loss; grade 1, areas of gland
loss < 33% of total gland area; grade 2, area of gland loss
between 33%–67% of total area; and grade 3, area of gland loss
> 67%). Scores for the upper and lower eyelids were added, to
obtain a total score (0–6) for each eye. Meibography images
were analyzed using ImageJ (http://imagej.nih.gov/ij/; provid-
ed in the public domain by the National Institutes of Health,
Bethesda, MD, USA), as described previously.20 During the
subjective and digital analysis of gland dropout, the investigator
was masked as to whether or not the participant had SS.
Statistical Analysis
Statistical analysis was conducted using Statistica 9 (StatSoft,
Tulsa, OK, USA). Scores for measured variables were recorded
as the combined average scores for both eyes. Differences in
measured variables between groups were compared using the
Mann-Whitney U test. Correlation between LLT, NITBUT, and
gland dropout was conducted using a Spearman rank
correlation. A P value of <0.05 was considered to be
significant.
RESULTS
There were 10 participants enrolled in the control group
(three men and seven women; age 58.5 6 4.7 years). Of the
participants, 11 were enrolled in the SS group (1 man and 10
women; age ¼ 56.0 6 9.1 years). None of the control group
and all 11 participants in the SS group reported the use of
artificial tear drops. Along with artificial tears, other commonly
reported methods to manage dryness symptoms among the SS
participants included the use of warm compresses, lid scrubs,
autologous serum, and cyclosporine eye drops, and omega-3
nutritional supplements.
The participants in the SS group had been diagnosed with
SS from 4 to 13 years prior. All participants reported that dry
eye symptoms preceded diagnosis of SS.
Median scores for the OSDI questionnaire, obstruction of
the central eight glands of the lower lid, quality of meibum,
staining scores, NITBUT, LIPCOF, LLT, gland dropout scores
using subjective grading, and gland dropout scores using the
digital grading are shown in the Table. Examples of images
taken by the Keratograph 4 and used for further analysis are
shown in the Figure.
There was a positive correlation between LLT and NITBUT
(r¼0.54; P < 0.05). There was a negative correlation between
digital dropout scores and NITBUT (r ¼ 0.60, P < 0.05).
There was no significant correlation between the digital and
subjective dropout scores with LLT.
DISCUSSION
The results of this study indicate that patients with SS have a
higher degree of MGD (poor quality, quantity, and morpholog-
ical changes) than adults who do not experience dry eye. The
presence and severity of MGD was evaluated by investigating
meibomian gland obstruction, expressibility, dropout, as well
as LLT and NITBUT. To our knowledge, this is the only study
that has investigated LLT and gland dropout, and the
relationship between the two in patients with SS. One other
study by Shimazaki et al.13 investigated gland dropout in
patients with SS and their findings support those from this
study, in that gland dropout was significantly higher in the SS
group. However, imaging of the gland dropout was not
undertaken with a contemporary infrared system and there
was no evaluation of LLT.
Historically, the dry eye experienced by people with SS has
been thought to be due to severe aqueous deficiency,38 with
little attention being paid to a possible role of evaporative dry
eye. Meibomian gland dropout is the most common cause of
evaporative dry eye.38–40 Dysfunction of the meibomian gland
is characterized by stenosis or obstruction of the gland
orifices on the lid margins, inflammatory changes (redness,
edema, telangiectasia), as well as quantitative and qualitative
changes to the secreted meibum.14 Stenosis of the gland
orifices prevents meibum from being secreted from the
glands. A build-up of meibum in the glands causes ductal
dilation, cystic degeneration, loss of the meibocytes, and
eventual gland atrophy.14 A reduction in meibum volume and
reduced quality of meibum secreted onto the ocular surface
TABLE. Average Scores and Respective P Values for the Control and SS Groups for NITBUT, LIPCOF, LLT, Subjective Gland Dropout Scores, and
Digital Gland Dropout Scores
Control Group SS Group
P ValueMedian (IQR) Median (IQR)
OSDI, scale 0–100 2.1 (0.0–2.6) 48.0 (23.0–56.2) <0.001*
Obstruction of central 8 glands, # of obstructed glands 2.5 (1.4–2.8) 8.0 (7.0–8.0) <0.001*
Quality of meibum, scale 0–3 0.5 (0.0–1.1) 2.0 (1.0–3.0) 0.002*
Staining score, scale 0–9 0.5 (0.5–0.5) 5.5 (3.5–6.5) <0.001*
LIPCOF, grade 0–3 2.0 (0.9–2.1) 2.5 (2.0–3.0) 0.2
NITBUT, sec 9.5 (6.4–17.6) 3.7 (2.5–4.2) <0.001*
LLT, nm 60.0 (45.0–100.0) 15.0 (15.0–15.0) 0.001*
MG dropout, subjective grading, grade 0–3, upper þ lower totaling to 6 1.0 (0.0–1.25) 1.5 (1.0–4.0) 0.03*
MG dropout, digital grading, 0%–100% 6.7 (1.5–12.7) 16.0 (12.1–40.0) 0.01*
* Statistically significant.
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leads to alterations and thinning of the lipid layer and
increased evaporation of the tear film.14 Alteration to the
lipid layer and LLT was evaluated in this study with the
Tearscope. The Tearscope permitted viewing of the tear film
lipid layer over the entire cornea, thus allowing evaluation of
the lipid layer in an undisturbed state. Past studies have used
the Tearscope to evaluate the lipid layer of potential and
current contact lens wearers, to determine if the lipid layer
would be suitable for lens wear, as well as to evaluate any
changes that occur to the thickness and stability of the lipid
layer during lens wear.27,28 The studies found that a thick
homogenous lipid layer, characterized as ‘‘amorphous,’’
tended to be the most stable.28 In this study, the participants
in the SS group presented with a significantly thinner lipid
layer, with the majority of the lipid layers characterized as
being an ‘‘open meshwork.’’ The positive correlation be-
tween LLT and NIBUT, with a thinner lipid layer being
correlated positively with a shorter NITBUT, follows the trend
previously reported by Maissa and Guillon.29 The shorter
NITBUT and thin LLT found in the SS group could be
explained further by the reduced quality of secreted meibum
in the SS group.
This study not only evaluated changes to the lid margin and
meibomian secretions, but also investigated the dropout of the
glands in the tarsal plates. Imaging meibomian glands in the
control and SS group was conducted successfully by using the
Keratograph 4, which has been used in previous work.20 The
participants in the SS group had a higher degree of meibomian
gland dropout, which likely contributed the thinner LLT and
shorter NITBUT, compared to individuals in the control group.
Our findings of more severe MGD and quicker evaporation
rates in participants with SS are in agreement with previous
studies.13,41
The subjective grading of meibomian gland dropout was
higher for the SS group compared to the control group.
Subjective grading has classically been used to evaluate gland
dropout. The 0 to 3 grading scale used by Arita et al.17,36,37 was
used in this study. A digital grading system reported by
Srinivasan et al.20 also was used to further evaluate the area of
functional meibomian glands which also demonstrated signif-
icantly higher dropout in the SS group compared to the control
group.
The mechanism of increased MGD found in SS to date has
not been extensively investigated. A study conducted by
Villani et al.42 investigated the histopathology of meibomian
FIGURE. (A) Meibography image of the upper eyelid of a participant in the normal group with no MGD. (B) Meibography image of the upper eyelid
of a participant in the SS group with MGD. (C) Meibography image of the lower eyelid of a participant in normal group with no MGD. (D)
Meibography image of the lower eyelid of a participant in SS group with MGD.
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glands in patients with primary and secondary SS using in
vivo confocal microscopy. The results showed signs of
inflammation of the meibomian glands that could be
responsible for increased MGD. Other research groups have
investigated the role of reduced androgen levels with
increased MGD.43,44 Krenzer et al.16 investigated whether or
not participants using antiandrogen therapy would develop
MGD. The results showed a decrease in tear breakup time, an
increase in gland orifice obstruction, and a decrease in the
quality of the meibomian secretions. These results suggest
that the drug therapy caused androgen deficiency that
ultimately led to MGD.16 Sullivan et al.45 investigated whether
patients with SS were androgen deficient, which may result in
meibomian gland dysfunction. In their study, the serum
concentrations of androgen precursors, active androgens, and
androgen metabolites were measured in 22 postmenopausal
women with SS, 10 with primary SS, and 12 with secondary
SS. Results showed a decrease in androgen levels compared to
normal controls that were age-matched, confirming that
patients with SS were, indeed, androgen deficient. Although
the results of these studies aid in the explanation of the
increased MGD of participants with SS in this current study,
serum androgen levels were not collected in this study nor
were the presence of inflammatory markers in the meibomian
glands, and, thus, it is difficult to conclude that reduced
androgen levels and inflammation contributed to the ob-
served increase in MGD.
It was interesting to note no differences between LIPCOF
values between the two groups, as it has been suggested to be
a valued determinant of dry eye.46 It has been shown that the
degree of LIPCOF intensity is significantly higher with
advancing age and more severe subjective symptoms.47,48
However, this was not the case in this study, as there were
significantly different subjective symptoms between groups
but similar LIPCOF values. The lack of significance between
the two groups may have been due to the small sample size for
each group, thus, more investigation with a larger sample size
is required to determine factors contributing to LIPCOF.
We recognize that there are a number of limitations to
this pilot study. This includes enrolling participants in the SS
group who had been diagnosed with either primary or
secondary SS and it is possible that systemic diseases in the
participants who had secondary SS may have contributed to
the meibomian gland loss. This warrants further investiga-
tion. In addition, the amount of time elapsed since diagnosis
was not controlled for in this study. A longer duration of the
disease, as well as a long time to diagnosis, may have
contributed to additional meibomian gland loss. Thus, future
studies on SS should perhaps consider only primary SS as an
inclusion criterion, as well as analyze onset of symptoms and
time since diagnosis. The LLT in this study was assessed
using the Tearscope, which allowed categorization of the
LLT according to the pattern observed. Although this
provides an indication of the corresponding range of
thickness, it does not provide the exact measurement of
the thickness of the lipid layer and further studies are
required to obtain accurate measurements of LLT in SS
patients. Another limitation to this study was not including a
group of participants with non-SS dry eye. Thus, it is difficult
for us to conclude with certainty that the increased MGD
seen in the SS group was specifically due to SS, rather than a
contribution of the dry eye symptoms found in all people
suffering from dry eye. Thus, it would be prudent for
another study to be conducted including a control group of
participants with non-SS dry eye.
In conclusion, this study showed that patients with SS
showed higher meibomian gland dropout scores and reduced
LLT and NITBUT, which likely contributed to the severe dry
eye symptoms reported by SS dry eye patients. This study
further supported previous work suggesting that dysfunction
of the meibomian glands has an essential role in severe dry
eye. This study also exemplifies the use of meibography for an
easy visualization and assessment of the degree of gland
dropout in patients with dry eye. Although the digital grading
system is time-consuming in a clinical setting, the subjective
method for analyzing the physical loss of meibomian glands
could aid in a better understanding and management of the
disease.
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